BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vaitla PM, Mcdermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology 2010;49:1040-8. [DOI: 10.1093/rheumatology/keq021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Che R, Xu H, Ding G, Zhao F, Huang S, Zhang A. Hemoperfusion and intravenous immunoglobulins for refractory gastrointestinal involvement in pediatric Henoch-Schönlein purpura: a single-center retrospective cohort study. BMC Pediatr 2022;22:692. [PMID: 36460986 DOI: 10.1186/s12887-022-03709-0] [Reference Citation Analysis]
2 Tocut M, Kolitz T, Shovman O, Haviv Y, Boaz M, Laviel S, Debi S, Nama M, Akria A, Shoenfeld Y, Soroksky A, Zandman-Goddard G. Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases. Autoimmun Rev 2022;21:103205. [PMID: 36195246 DOI: 10.1016/j.autrev.2022.103205] [Reference Citation Analysis]
3 Öner N, Çelikel E, Tekin ZE, Güngörer V, Kurt T, Tekgöz PN, Sezer M, Karagöl C, Coşkun S, Kaplan MM, Polat MC, Acar BÇ. Intravenous immunoglobulin therapy in immunoglobulin A vasculitis with gastrointestinal tract involvement. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00950-w] [Reference Citation Analysis]
4 Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergström J, Ingelsson M, Syvänen S, Sehlin D. Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics 2022;14:1412. [DOI: 10.3390/pharmaceutics14071412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chalayer E, Gramont B, Zekre F, Goguyer-Deschaumes R, Waeckel L, Grange L, Paul S, Chung AW, Killian M. Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev 2021;21:103016. [PMID: 34915182 DOI: 10.1016/j.autrev.2021.103016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lewis BJB, Ville J, Blacquiere M, Cen S, Spirig R, Zuercher AW, Käsermann F, Branch DR. Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer. BMC Immunol 2019;20:44. [PMID: 31801459 DOI: 10.1186/s12865-019-0328-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Mauro A, Mauro S, Rega R, Martemucci L, Sottile R. Successful treatment of hemorrhagic bullous Henoch-Schonlein purpura with intravenous immunoglobulins. Pediatr Dermatol 2019;36:e34-6. [PMID: 30561101 DOI: 10.1111/pde.13715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Seredavkina NV, Reshetnyak TM, Nasonov EL. Complicated management of patients with systemic lupus erythematosus. Klin med 2018;96:463-471. [DOI: 10.18821/0023-2149-2018-96-5-463-471] [Reference Citation Analysis]
9 Gameiro RS, Reis AIA, Grilo AC, Noronha C. Following leads: connecting dysphagia to mixed connective tissue disease. BMJ Case Rep 2018;2018:bcr-2017-223699. [PMID: 29507032 DOI: 10.1136/bcr-2017-223699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Finke JM, Banks WA. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Hum Antibodies 2017;25:131-46. [PMID: 28035915 DOI: 10.3233/HAB-160306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kalden JR. Biologika. Z Rheumatol 2016;75:604-610. [DOI: 10.1007/s00393-016-0122-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Lee MJ, Lim E, Mun S, Bae S, Murata K, Ivashkiv LB, Park-Min KH. Intravenous Immunoglobulin (IVIG) Attenuates TNF-Induced Pathologic Bone Resorption and Suppresses Osteoclastogenesis by Inducing A20 Expression. J Cell Physiol 2016;231:449-58. [PMID: 26189496 DOI: 10.1002/jcp.25091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
13 Dumoitier N, Terrier B, London J, Lofek S, Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmunity Reviews 2015;14:996-1004. [DOI: 10.1016/j.autrev.2015.06.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
14 Guidelli GM, Tenti S, Pascarelli NA, Galeazzi M, Fioravanti A. Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature. Autoimmunity Reviews 2015;14:659-64. [DOI: 10.1016/j.autrev.2015.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
15 Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev 2015;14:651-8. [PMID: 25870941 DOI: 10.1016/j.autrev.2015.04.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
16 Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 2014;33:531-6. [DOI: 10.1007/s10067-013-2478-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
17 Pego PM, Câmara IA, Andrade JP, Costa JM. Intravenous immunoglobulin therapy in vasculitic ulcers: a case of polyarteritis nodosa. Auto Immun Highlights 2013;4:95-9. [PMID: 26000148 DOI: 10.1007/s13317-013-0048-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Rozman Z, Zandman-goddard G. Intravenous immunoglobulin therapy for SLE. Immunotherapeutic Agents for SLE 2012. [DOI: 10.2217/ebo.11.328] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Cheng MJ, Christmas C. Special Considerations with the Use of Intravenous Immunoglobulin in Older Persons: . Drugs & Aging 2011;28:729-36. [DOI: 10.2165/11592740-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
20 Hughes GR. Hughes syndrome (the antiphospholipid syndrome): a disease of our time. Inflammopharmacology 2011;19:69-73. [PMID: 21132565 DOI: 10.1007/s10787-010-0071-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]